First-in-Humans Study of 68Ga-DOTA-Siglec-9, a PET Ligand Targeting Vascular Adhesion Protein 1

Conclusion: Intravenous injection of 68Ga-DOTA-Siglec-9 was safe and biodistribution was favorable for testing of the tracer in larger group of patients with rheumatoid arthritis, as is planned for the next phase of clinical trials. The effective radiation dose of 68Ga-DOTA-Siglec-9 was within the same range as the effective radiation doses of other 68Ga-labeled tracers. Injection of 150 MBq of 68Ga-DOTA-Siglec-9 would expose a subject to 3.3 mSv. These findings support the possible repeated clinical use of 68Ga-DOTA-Siglec-9, such as in trials to elucidate the treatment efficacy of novel drug candidates.

Source: Journal of Nuclear Medicine - March 29, 2021 Category: Nuclear Medicine Authors: Viitanen, R., Moisio, O., Lankinen, P., Li, X.-G., Koivumaki, M., Suilamo, S., Tolvanen, T., Taimen, K., Mali, M., Kohonen, I., Koskivirta, I., Oikonen, V., Virtanen, H., Santalahti, K., Autio, A., Saraste, A., Pirila, L., Nuutila, P., Knuuti, J., Jalkane Tags: Translational Source Type: research